Single-Cell-Derived Tumor Organoid (STO) arrays on a microfluidic chip for personalized drug screening to address heterogeneity-induced drug resistance in colorectal cancer
Open Access
- 22 December 2025
- journal article
- research article
- Published by Springer Nature in Microsystems & Nanoengineering
- Vol. 11 (1) , 253
Abstract
Tumor heterogeneity drives chemotherapy resistance in cancer, necessitating the development of strategies to target diverse cellular subpopulations. Single-cell-derived tumor organoids (STOs), derived from individual tumor stem cells (TSCs), retain well-defined genomic and phenotypic attributes, making them instrumental in elucidating unique diversification. Here, we developed a microfluidic approach that utilizes STO arrays for personalized drug screening, aimed at overcoming heterogeneity induced drug resistance in colorectal cancer. We utilized a microwell array format microfluidic chip to the generation of a high scale STO array. This array encompasses two key features: (1) STOs in individual microwells are derived from single TSCs, which allows for a high-resolution display of cellular heterogeneity; (2) it exhibits thousands of STOs at predefined locations on the same focal plane, thereby facilitating automated, high-content analyses using imaging data. Utilizing the STO array, we assess the responses of various subpopulations of colorectal cancer to a conventional chemotherapeutic regimen, facilitating the phenotypic identification of resistant STOs. Through the analysis of RNA sequencing data from the resistant STOs, candidate drugs targeting resistance-associated pathways were identified for individual patients. Furthermore, the candidate drugs were validated through STO-array drug testing, demonstrating enhanced clearance effects when combined with the conventional regimen. Our study establishes a scalable, patient-specific drug screening approach that integrates phenotypic and molecular analyses, offering a transformative strategy to overcome heterogeneity-driven drug resistance in colorectal cancer. The microfluidic platform presented herein holds significant potential for advancing precision oncology and personalized therapeutic design.Keywords
This publication has 36 references indexed in Scilit:
- Colorectal Cancer Patient‐Derived 2D and 3D Models Efficiently Recapitulate Inter‐ and Intratumoral HeterogeneityAdvanced Science, 2022
- Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug ResponsesAdvanced Science, 2021
- Consequence of distinctive expression of MUC2 in colorectal cancers: How much is actually bad?Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Bioinspired One Cell Culture Isolates Highly Tumorigenic and Metastatic Cancer Stem Cells Capable of Multilineage DifferentiationAdvanced Science, 2020
- A Droplet Microfluidic System to Fabricate Hybrid Capsules Enabling Stem Cell Organoid EngineeringAdvanced Science, 2020
- Targeting the MAPK Pathway in KRAS-Driven TumorsCancer Cell, 2020
- Intratumor Heterogeneity: The Rosetta Stone of Therapy ResistanceCancer Cell, 2020
- Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?Cellular and Molecular Gastroenterology and Hepatology, 2020
- Spatial and temporal clonal evolution of intrahepatic cholangiocarcinomaJournal of Hepatology, 2018
- Chromogranin‐a expression in gastric and colon cancer tissuesInternational Journal of Cancer, 1992